✦ LIBER ✦

A phase I trial with recombinant interferon γ (Roussel UCLAF) in advanced cancer patients

✍ Scribed by François Boue; Zulay Pastran; Marc Spielmann; Thierry Le Chevalier; Rosana Subirana; Dominique Sevin; Catherine Paoletti; Maud Brandely; Marie-Françoise Avril; Hélène Sancho-Garnier; Thomas Tursz

Publisher: Springer-Verlag
Year: 1990
Tongue: English
Weight: 503 KB
Volume: 32
Category: Article
ISSN: 0340-7004
DOI: 10.1007/bf01741727

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I trial of recombinant gamma int

A phase I trial of recombinant gamma interferon in patients with cancer

✍ Kenneth A. Foon; Stephen A. Sherwin; Paul G. Abrams; Henry C. Stevenson; Pamela 📂 Article 📅 1985 🏛 Springer-Verlag 🌐 English ⚖ 461 KB

Recombinant gamma interferon in advanced

Recombinant gamma interferon in advanced breast cancer: A phase II trial

✍ Hyman B. Muss; Mary Caponera; Patricia J. Zekan; Don V. Jackson; John J. Stuart; 📂 Article 📅 1986 🏛 Springer US 🌐 English ⚖ 365 KB

Fifteen patients with advanced carcinoma of the breast who had failed prior chemotherapy, were treated with recombinant gamma interferon at a dose of 2mg/m2 (1mg = 2.4 X 10(7) international units) intravenously for five consecutive days every other week. The median patient age was 51 and all patient

A phase I-II trial of the combination of

A phase I-II trial of the combination of recombinant leukocyte a interferon and recombinant human interferon-γ in patients with metastatic malignant melanoma

✍ Edward T. Creagan; Charles L. Loprinzi; David L. Ahmann; Daniel J. Schaid 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 325 KB 👁 2 views

Treatment of systemic sclerosis with rec

Treatment of systemic sclerosis with recombinant interferon-γ. A phase I/II clinical trial

✍ Bruce Freundlich; Sergio A. Jimenez; Virginia D. Steen; Thomas A. Medsger Jr.; M 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 839 KB

A Phase I trial of weekly lomustine in p

A Phase I trial of weekly lomustine in patients with advanced cancer

✍ Charles A. Koller; Carolyn C. Gorski; Robert S. Benjamin; Sewa S. Legha; Nichola 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 374 KB 👁 2 views

Long-term intravenous hydroxyurea infusi

Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trial

✍ Martin S. Blumenreich; Michael J. Kellihan; U. Geetha Joseph; Kim A. Lalley; Eli 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 384 KB 👁 1 views

Background. Hydroxyurea is an S-phase specific drug. Constant exposure of tumor cells with a low Sphase fraction to the agent may result in improved cell kill. Because of its short half-life, a continuous intravenous infusion may result in better tumor exposure than intake by mouth. The goal of this